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Cardiac PET: A Versatile, Quantitative
Measurement Tool for Heart Failure
Management
Henry Gewirtz, MD
Boston, Massachusetts
Current American Heart Association/American College of Cardiology practice guidelines classify conges-
tive heart failure (CHF) in 4 stages (A, B, C, and D). This review focuses on state-of-the-art and future
applications of quantitative positron emission tomography (PET) myocardial perfusion and metabolic
imaging in the clinical evaluation and treatment of patients in all CHF stages. Basic physiological and
metabolic principles related to the regulation of myocardial blood flow andmetabolism at various stages
of CHF are briefly reviewed. The advantages of quantitative PET image analysis in contrast to simple
qualitative visual analysis of the scans alsowill be addressed. Finally, potential future clinical applicationsof
quantitative PET for CHF evaluation and treatment will be discussed. (J Am Coll Cardiol Img 2011;4:
292–302) © 2011 by the American College of Cardiology Foundationchus
fromCurrent American Heart Association/American
College of Cardiology guidelines recommend
consideration of congestive heart failure (CHF)
in 4 stages (A, B, C, and D; Fig. 1) (1). Stages
A and B represent preclinical CHF (stage A:
patient at high risk but without structural
heart disease; stage B: structural heart disease
present but symptoms/signs of CHF absent).
Stages C and D reflect overt CHF (stage C:
structural heart disease present with prior or
current symptoms of CHF; stage D: refrac-
tory CHF requiring specialized interven-
tion). The incidence of CHF in the United
States has been increasing steadily in recent
years (400,000 new cases every year estimated
by the National Heart, Lung and Blood
Institute in 1996), and mortality, particularly
in stage D, is in excess of 50% per year (2).
Accordingly, the syndrome represents a ma-
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disease (IHD) and hypertension are the most
common causes of CHF, although obesity
and diabetes, even in the absence of overt
IHD but frequently present together and
often with hypertension, are increasingly rec-
ognized as common etiologies (2). Quantita-
tive positron emission tomography (PET)
imaging plays an important role in both
diagnosis of etiology and assessment of treat-
ment of CHF at various stages of the syn-
drome and provides prognostic information
as well. The current state of the art and
future directions for quantitative PET imag-
ing in CHF is the focus of this review, which
will also address the advantages of the quan-
titative approach in contrast to simple qual-
itative visual interpretation of PET cardiac
images.
etts General Hospital, Harvard Medical School,
FluoroPharma, Inc.ecember 20, 2010, accepted December 23, 2010.
[r
k
f
t
C
O
e
c
t
f
t
m
i
s
C
m
i
o
s
m
v
[
raphy
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 3 , 2 0 1 1
M A R C H 2 0 1 1 : 2 9 2 – 3 0 2
Gewirtz
Quantitative PET for Evaluation of Patients With HF
293Quantitative PET Imaging in Patients With CHF:
State of the Art
The role for state-of-the-art quantitative PET
measurement of myocardial blood flow (MBF)
(Fig. 2) and metabolism (glucose and fatty acid)
depends on the specific clinical question(s) to be
addressed. However, in more general terms, there
are several points that should be made concerning
the advantages of quantitative versus qualitative
simple visual analysis of cardiac PET images in
patients with CHF. First, simple visual analysis of
PET myocardial perfusion images requires the as-
sumption of a “normal” perfusion or metabolic
zone—an erroneous assumption and clearly a major
limitation of that approach. Second, simple visual
interpretation is by definition subjective and hence
liable to all associated shortcomings. Third, it has
been shown in a modern clinical trial (PARR 2
[PET and Recovery Following Revascularization])
(3,4) and older observational studies (5–9) that
objective measurement of parameters indicative of
myocardial viability or myocardial flow reserve are
valuable in improving patient management or as-
sessing prognosis in patients with CHF. Such
parameters (e.g., quantitative, objective determina-
tion and extent of MBF/18F-fluorodeoxyglucose
FDG] “mismatch” and 82Rb myocardial tracer
kinetics and measurement of myocardial flow re-
serve) necessitate state-of-the-art quantitative PET
imaging of MBF and metabolism and cannot be
obtained by simple visual analysis of static PET
images. Finally, potential future clinical applica-
tions for PET cardiac imaging in CHF (e.g., risk
assessment for sudden cardiac death in patients
with ischemic cardiomyopathy; PARAPET [Pre-
diction of Arrhythmic Events With Positron Emis-
sion Tomography] trial) (10–13) will depend on
adoption of current state-of-the-art quantitative
PET methodologies used in such trials for assess-
ment of MBF, glucose metabolism, and sympa-
thetic nervous system function.
Pathophysiology of MBF and Clinical Applications
of PET in Left Ventricular Dysfunction and CHF
Ischemic cardiomyopathy. Endothelial dysfunction
elated to dyslipidemia and oxidant stress (14,15) is
nown to affect the coronary microcirculation be-
ore the onset of overt coronary atherosclerosis and
herefore places affected individuals in stage A
HF (high risk, without structural heart disease).
ngoing dyslipidemia, oxidant stress, and resultingndothelial dysfunction commonly progress to overt
oronary atherosclerosis (stage B CHF), which in
urn may be complicated by acute myocardial in-
arction and resulting left ventricular (LV) dysfunc-
ion or frank CHF (stage C CHF). Extensive
yocardial damage from either a single or multiple
nfarcts may result in refractory CHF requiring
pecialized treatment or intervention (stage D
HF). Positron emission tomography measure-
ents of absolute myocardial blood flow play an
mportant role in patient management at each stage
f CHF related to IHD or predisposing conditions
uch as obesity, hypertension, diabetes, dyslipide-
ia, and smoking. PET assessment of myocardial
iability (typically with combined MBF and glucose
18F-FDG] metabolism study) is especially impor-
tant in stages C and D CHF.
The role of PET measurements of MBF in assess-
ment of coronary microvascular function has
been reviewed extensively (14–16). Even
asymptomatic patients with dyslipidemia
without manifest IHD may have abnormal
myocardial flow reserve owing to coronary
microvascular dysfunction (17). The same is
true of patients with obesity, diabetes, and
hypertension either alone or in combination
(18). A common mechanism in each of
these conditions is endothelial dysfunction
related to oxidant stress and subsequent
reduction in nitric oxide bioavailability (18–
21). Depending on whether or not LV
hypertrophy is present in association with
hypertension, mechanical compressive forces
and interstitial fibrosis also may play a role
(22). Circulating vasoactive peptides (e.g.,
endothelin) (23) also may contribute to impairment of
coronary microvascular dilator capacity. Finally, it has
been shown that evidence of increased serum levels of
circulating biomarkers of inflammation increase the
risk of developing CHF (24–26) and may do so at
least in part via the oxidant stress mechanism noted
earlier.
Several small observational studies in humans
have suggested that PET measurements of absolute
MBF and MBF reserve may be useful in providing
prognostic information concerning progression
from stage A/B to C/D CHF in patients with
hypertrophic (5,27) or idiopathic dilated cardiomy-
opathy (DCM) (7). Although the studies have
certain limitations in addition to small sample size,
such as reliance on flow reserve ratio as an end
point, they nevertheless demonstrated the potential
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from simple qualitative visual analysis of the images.
Similar data regarding prognosis have been reported
for patients with IHD (28). More widespread
application of clinical insights derived from these
studies is now possible with generator-derived 82Rb
for PET measurements of absolute MBF and MBF
reserve with a commercially available Food and
Drug Administration–approved computer program
Figure 1. American Heart Association/American College of Ca
ASCVD  atherosclerotic cardiovascular disease; CHF  congestive
fraction; LVH  left ventricular hypertrophy; MI  myocardial infarc
Parametric 13N-Ammonia Myocardial Blood Flow Images
scale (ml/min/g) is shown at the right for rest, adenosine (ADO),r
amine (DBTMN) conditions in a healthy human subject.(Corridor 4DM, CFR option, INVIA Medical
Imaging Solutions, Ann Arbor, Michigan). The
program has been validated by comparison with
13N-ammonia measurements of MBF in humans
(29) and therefore is suitable for use with 13N-
ammonia as well. As noted earlier, use of quantita-
tive measurements of MBF do not depend on the
invalid assumption of an obligatory “normal” zone
and so are inherently superior to simple qualitative
visual assessment of these images. Further, as 18F-
labeled MBF tracers (e.g., 18F-BMS-747158-02
[30] and possibly 18F-BFPET [31]) become available,
he ability to make these measurements will become
ven more widespread. In addition to providing prog-
ostic information, which may be helpful in guiding
HFmanagement at an early stage, quantitative PET
easurements of MBF will permit establishment of
aseline pre-treatment levels of maximal MBF and
herefore provide an objective parameter for subse-
uent follow-up exams designed to assess the effects
f therapy (e.g., statins [32]) in patients judged to
e at high risk for progression to more advanced
tages (C and D) of CHF.
The use of PET quantitative assessment of ab-
olute MBF and myocardial glucose metabolism is
ore clearly established in the setting of stages C
nd D CHF. When signs and symptoms of CHF
re first manifest but the etiology has not been
stablished, it is common practice to perform diag-
ostic cardiac catheterization and coronary angiog-
logy Guideline for Clinical Staging of CHF
rt failure; LV  left ventricular; LVEF  left ventricular ejection
.rdio
heaFigure 2.
The coloraphy. However, PET quantitative assessment of
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295absolute MBF will be very helpful in a variety of
settings. Patients with chronic renal insufficiency,
not yet on dialysis, are at high risk for severe
worsening of renal function with coronary angiog-
raphy. PET quantitative assessment of absolute
MBF with 13N-ammonia or 82Rb is an excellent
method for assessment of the coronary circulation
in such cases. Detection of hemodynamically signif-
icant stenoses in each of the 3 major coronary vascular
territories is possible with a single MBF measurement
obtained during adenosine infusion (33). The same
methodology also should be considered for patients
whose prior probability for IHD is low (10%) and
certainly for those with coronary stenoses of uncertain
physiological significance (see the following paragraph
and Figure 3).
PET quantitative assessment of absolute MBF
during adenosine stress may be thought of as a
noninvasive fractional flow reserve test (33) (Fig. 3).
In this regard, it should be noted that coronary
intervention(s) performed in patients with abnormal
fractional flow reserve were associated in the FAME
(Fractional Flow Reserve Versus Angiography for
Multivessel Evaluation) trial (34) with reduced rates of
the primary end point at 1 year (death, nonfatal
myocardial infarction, and repeat revascularization)
compared with that of similar patients in whom
percutaneous coronary interventions were performed
based on visual assessment of the lesions alone. This
study thus provided another example of the superiority
of objective physiological assessment over simple qual-
Figure 3. Schematic Representation of the Physiological Basis f
The pressure drop (dP) across a coronary stenosis is given by the e
stenosis geometry and blood viscosity (80–82). Under conditions in
approaches 0, and so there is no dP along the epicardial vessel dur
is approximately 1 (mean aortic pressure [Pao]  mean pressure di
a and b increase and, more importantly, ﬂow accelerates across the na
(note the term bQ2), with resulting decline in Pd. Thus, FFR becomes mucitative visual inspection of images in the evaluation
and treatment of patients with IHD. Moreover, ac-
quiring an electrocardiogram-gated image of the myo-
cardium following completion of the dynamic acqui-
sition for MBF measurements makes it possible to
assess LV function, including LV volumes, LV ejec-
tion fraction, and stroke work and power (35–37).
These measurements of LV contractile function not
only are useful in following the response to therapy but
also are essential to the proper interpretation of abso-
lute measurements of MBF in the case of stroke work
and power.
PET measurements of absolute MBF also have
been employed in the past to help elucidate the
pathophysiology of myocardial hibernation and
stunning (38–44), which are frequently present in
stages C and D CHF. Although it is clear that a
chronic state characterized by matched reduction of
MBF and contractile function (hibernation) exists
in humans (41), chronic stunning (relatively pre-
served MBF with impaired contraction) also is
known to occur (44), sometimes in the same pa-
tients (41), and may progress to chronic hibernation
(42). These states are of considerable importance in
the clinical evaluation of patients with IHD with
stages C and especially D CHF. In particular,
efforts to detect myocardial viability in one or more
coronary vascular territories frequently play a key
role in clinical decision making regarding revascu-
larization.
The established PET method for assessment of
myocardial viability compares the uptake of 18F-
FR Measurement
ion dP  aQ  bQ2, for which a and b are constants related to
ich there is no stenosis (A), the value of each constant
adenosine infusion. Accordingly, the fractional ﬂow reserve (FFR)
to the stenosis [Pd]). With increasing stenosis severity, the values of
ed vessel lumen (B) such that there is a geometric pressure lossor F
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296FDG with that of rest MBF (9), as represented by
static PET 13N-ammonia or 82Rb uptake images.
egions with 18F-FDG uptake in excess of MBF
“mismatch”) generally are viable and have been
hown to improve contraction following revascular-
zation (6,9,41). It is important to note that the
riginal description of the observation (9) and
ecent clinical trials (4,45) used quantitative nor-
alized measurement of tracer concentration and
tandardized definitions to determine the presence
nd extent of 18F-FDG MBF “mismatch.” Simple
qualitative visual assessment was not used. More-
over, the extent of FDG/blood flow “mismatch,”
objectively measured, has been shown both to have
prognostic information and to be helpful in decision
making regarding coronary revascularization in
ischemic cardiomyopathy (3,4,6). Such information
is not available from simple visual analysis of the
images. Accordingly, to obtain optimal results,
especially to define the extent of “mismatch” terri-
tory, state-of-the-art clinical practice should apply
methods shown to be of value in prior clinical trials.
Although, in theory, Patlak analysis to determine
the metabolic rate for glucose usage combined with
absolute measurement of MBF should be superior
to the quantitative normalized method for deter-
mining viability precisely because it avoids the
assumption of an obligatory “normal” zone (typi-
cally that with the best 13N-ammonia or 82Rb
ptake), this approach has not been reported and
emains a direction for future research.
PET measurements of absolute MBF alone in
his setting are predictive of myocardial scar at very
ow flows, 0.3 ml/min/g, which commonly cor-
espond to regions of poor 18F-FDG uptake
38,46,47). However, at higher levels of rest MBF,
verlap between viable and nonviable regions pre-
ludes exclusive use of absolute MBF for viability
ssessment (Fig. 4). Nevertheless, quantitative mea-
urements of PET 82Rb washout (8) or 13N-
ammonia tracer kinetic parameters (e.g., K1/k2
[46] and k3 [47]), which cannot be obtained from
simple visual analysis of uptake images, have been
shown to enhance detection of viable myocardium
in patients with ischemic cardiomyopathy and in
conjunction with absolute measurement of MBF
suggest a potential future alternative to 18F-FDG
MBF “mismatch” for viability assessment.
Another PET method, measurement of myocar-
dial oxygen consumption with 11C-acetate, has
been used to assess myocardial viability and was
shown to be superior to that of 18F-FDG in one lab
48). The method is limited, however, by the needor an on-site cyclotron to produce the tracer and
herefore has not gained widespread acceptance.
inally, it should be noted that cardiac magnetic
esonance (CMR), with gadolinium contrast and
ulse sequence designed to optimize delayed (5 to
0 min post–contrast injection) hyperenhancement
f scar tissue (49), has been found to be an accurate
ethod for assessment of myocardial viability, com-
ares quite favorably with PET 18F-FDG method-
ology (50), and is becoming increasingly used for
this purpose.
Other potential applications for PET measure-
ments of absolute MBF that have not yet achieved
wide clinical application but are pertinent, particu-
larly to stage D CHF, often but not always of
ischemic origin, include baseline and follow-up
measurements in patients after cardiac transplant
(51–54) and those with LV assist device support
(55) or cardiac resynchronization therapy with
biventricular pacemaker (56). Follow-up of patients
after cardiac transplantation represents perhaps the
most useful of these potential applications, given
the importance of post-transplant coronary artery
vasculopathy (CAV) in determining the clinical
course of these patients (57). Coronary angiogra-
Figure 4. Group Mean ( SD) Data Depicting the Relationship
Between Rest MBF and Myocardial Viability as Deﬁned by
PET, ECHO, and Contractile Response to CABG Criteria
By all 3 methods, regions of chronically reduced myocardial
blood ﬂow (MBF) corresponded to viable myocardial segments.
In the MBF range of  0.3 ml/min/g, there is considerable over-
lap between viable and nonviable segments. Reprinted, with
permission, from Tawakol et al. (41). CABG  coronary artery
bypass graft; ECHO  echocardiography; NZ  normal zone;
PET  positron emission tomography.phy, coronary intravascular ultrasound (IVUS), or
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297both are routinely employed annually to detect
anatomic evidence of epicardial coronary stenoses or
diffuse intimal thickening of varying degree related
to CAV (57–59). Both methods are invasive and
provide anatomic as opposed to functional informa-
tion concerning the status of coronary circulation.
Moreover, because of diffuse intimal thickening, the
epicardial coronary vessels may appear angiographi-
cally normal (58,59), whereas disease primarily
involving very small intramyocardial vessels includ-
ing the microcirculation (51,60) cannot be visual-
ized by routine angiography or IVUS.
Because the vasodilator capacity of the coronary
microcirculation changes as a function of time
post-transplant even in the absence of epicardial
stenoses (51), it is important in interpreting PET
measurements of absolute MBF (rest and with
adenosine or other direct coronary vasodilator) to be
cognizant of the duration post-transplant at the
time of measurement (Fig. 5). In the first year
post-transplant, rest MBF may be elevated relative
to demand, although dilator capacity is normal (vs.
healthy controls) (51). Between 1 and 3 years
post-transplant, both rest MBF and maximal dila-
tor capacity typically are normal. However, after 3
years, microvascular dilator capacity declines versus
normal (51). A rough inverse correlation between
extent of intimal thickening by IVUS (plaque vol-
ume) and myocardial flow reserve assessed by PET
13N-ammonia recently has been reported (52). The
loose inverse relationship clearly illustrates the well-
known problem of comparing anatomic with phys-
iological measurements and, more importantly,
raises the question of which is better for assessment
of prognosis and evaluation of therapy aimed at
preventing or at least ameliorating CAV. Although
the answer is not known, it appears likely that the
functional measurements (i.e., absolute MBF) may
prove superior because in the case of coronary
microcirculation, abnormal vasodilator capacity re-
lated to abnormal endothelial function precedes
recognizable structural abnormalities.
Stem cell and gene therapy to treat stages C and
D CHF, particularly that related to IHD, is an
active research area. Whereas studies with positron-
emitting reporter probes (61) have sought to docu-
ment the presence, location, and fate of engrafted
cells or gene expression, functional studies of the
coronary circulation in such patients have been
limited and involved standard single-photon emis-
sion computed tomography myocardial perfusion
imaging (62). However, a recent PET study of aMBF reserve in patients treated with vascular en-
dothelial growth factor has been reported (63).
Given that the placebo effect is known to compli-
cate interpretation of these studies, objective meth-
ods to document improvement are essential not
only in the research setting but also for subsequent
clinical management. Indeed, a recent pilot study
employed both quantitative PET measurements of
MBF (13N-ammonia) and 18F-FDG for glucose
etabolism to define viability by objective criteria
nd obtain gated 18F-FDG images for objective
easurement of LV function in patients treated
ith bone marrow–derived stem cells following
yocardial infarction (64). Although preliminary,
uantitative PET data identified a subset of patients in
hom stem cell therapy appeared to reduce scar size
nd improve rest MBF and LV function. The study is
llustrative of the role and future direction for state-
f-the-art quantitative PET measurements of MBF
nd metabolism in assessment of the efficacy of state-
f-the-art therapy for stages C and D CHF.
Nonischemic cardiomyopathy. Obesity, diabetes, and
ypertension commonly coexist in a given patient
Figure 5. Group Mean ( SD) Data Depicting the Time
Course of Changes in Rest and Minimal (Adenosine) CVR
Following Cardiac Transplantation in Humans With
Normal Coronary Angiograms
Note that in the early post-transplant period, rest coronary vas-
cular resistance (CVR) is reduced versus both normal controls
(WNL) and other transplant groups (1 year, 1–3 years, and 3
years). More than 3 years following cardiac transplantation,
there is evidence of progressive microvascular dysfunction with
a signiﬁcant increase in minimal CVR. *p  0.05 versus other
groups. Reprinted, with permission, from Kushwaha et al. (51).
Ado  adenosine; WNL  within normal limits.nd either alone or in combination may result in
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298DCM absent atherosclerotic coronary artery dis-
ease. In addition to important coronary microvas-
cular dysfunction in these patients (14,15), abnor-
malities in both glucose and fatty acid metabolism
are known to occur and have been reviewed in detail
recently (65–69). Although beta oxidation of free
fatty acids (FFA) is the principal source of ATP
production by cardiomyocyte mitochondria under
resting conditions in the normal heart, it is impor-
tant to recall that glucose also is used and that the
substrate utilization will vary depending on the
metabolic milieu and physiological conditions
(65,67). Thus, with exercise, glucose usage increases
relative to FFA beta oxidation. Moreover, it has
been pointed out from a metabolic view that the
heart does best when using an appropriate mix of
carbohydrate and FFA as fuels (Fig. 6) and that
excessive shift to either glucose or FFA metabolism
may result in cardiotoxicity (67,68).
Diabetes has been noted to be an important exam-
ple in which insulin resistance leads to excessive use of
FFA by the myocardium, with resulting lipotoxicity
(68,69). Under such conditions, the heart’s ability to
oxidize FFA (and glucose) is impaired, and conse-
quently ATP production declines, with the result that
the heart behaves as “if starved in the midst of plenty”
(66–69). Lipotoxicity is associated with a number of
other maladaptive processes including accumulation of
triglycerides, reactive oxidant species, and activators of
various genetic transcription factors (68,69). In addi-
tion, excessive FFA metabolism inhibits glucose oxi-
dation and results in accumulation of intermediary
products of glycolysis. These products are potentially
cardiotoxic and may active genetic pathways, particu-
larly fetal programs, that may become maladaptive
(70), and together result in what has been termed
glucolipotoxicity (69,71). Finally, it has been reported
that more advanced stages of CHF (C and D) may
Figure 6. Schematic Representation of Myocardial Use of FA an
Under physiological conditions, the myocardium employs a mixture
tion. Excessive reliance on one or the other is maladaptive and lead
as glucolipotoxicity (69).themselves causemyocardial insulin resistance and there-
fore result in a vicious cycle in which CHF impairs
intermediate energy metabolism, which in turn exacer-
bates CHF (70,72).
Currently, there is great research potential for
PET imaging of cardiac metabolic pathways and
gene programs involved in the basic mechanisms
underlying CHF of ischemic and nonischemic eti-
ologies at all stages (66,73). Clinical applications,
unfortunately, are limited by a number of factors,
including requirement for an on-site cyclotron and
radiochemist to manufacture 11C-labeled metabolic
intermediates and complexity of the studies that
range from patient dietary preparation to advanced
tracer kinetic models needed for quantitative re-
sults. It may be possible in the future to minimize
many of these issues with a previously reported
18F-labeled fatty acid tracer (74).
One quantitative study with 18F-FDG in humans
nder conditions of a hyperinsulinemic, euglycemic
lamp demonstrated that young patients with insulin-
ependent diabetes of 5 years’ duration had similar
nsulin-stimulated myocardial glucose uptake com-
ared with healthy controls (75). Further, given cur-
ent interest in cardiac metabolism as a target for
HF therapy at various stages (67,70,76), the ability
o quantitatively measure glucose use with 18F-FDG
n humans (Fig. 7) under well-defined metabolic and
emodynamic conditions may prove helpful in deter-
ining if a particular therapy (drug or device) en-
ances myocardial glucose usage, which is more effi-
ient in comparison with FFA beta oxidation in terms
f oxygen consumption for production of ATP (70).
oreover, the ability to gate the FDG acquisition
ermits near simultaneous assessment of LV contrac-
ile function (64,77) and therefore provides direct
nformation on the therapeutic efficacy of the meta-
olic intervention. Accordingly, quantitative PET
O in the Human Heart
fatty acids (FA) and carbohydrates (CHO) to fuel energy produc-
lipotoxicity (FA), glucotoxicity (CHO), or a combined state knownd CH
of
s to
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299measurements of cardiac glucose metabolism and
contractile function are readily available in the clinical
setting and are likely to play a more important role in
patient management as metabolic interventions be-
come more widely applied and the need to demon-
strate efficacy increases in a socioeconomic environ-
ment that demands the optimal use of scarce health
care resources.
Further, it may be anticipated that the advent of
18F-labeled fatty acid and sympathetic nerve (78)
tracers will substantially expand the field of cardiac
metabolic and autonomic nervous system imaging for
clinical use in patients with CHF, especially when
combined with quantitative measurements of glucose
metabolism, LV function. and MBF. Lastly, quanti-
tative PET imaging of 18F-FDG in humans has been
reported useful in distinguishing idiopathic DCM
from that owing to isolated cardiac sarcoidosis and for
assessing both disease activity and response to therapy
(79). The quantitative methodology employed re-
quired determination of standard uptake values of
18F-FDG in a standard 17-segment model, along
with means, SDs, and coefficients of variation, all of
which are not possible with simple qualitative visual
analysis. The last parameter (coefficients of variation)
was essential to objectively defining “heterogeneous”
tracer uptake and best separated patients with cardiac
sarcoidosis from those with DCM, as well as controls
and patients with sarcoidosis but without cardiac
involvement.
Conclusions
PET quantitative measurements of MBF and metab-
olism provide state-of-the-art methodology for eval-
uation and management of patients at all stages of
CHF. In stages A and B, quantitative measurements
of absolute MBF permits assessment of coronary
microvascular function, which are impossible to obtain
with simple visual analysis of uptake images and which
have been shown to provide prognostic information
(5,7) and information on response to therapy (32). In
the more advanced stages of CHF (C and D), quan-
titative PET measurements of MBF and glucose
metabolism are of proven value in assessment of
myocardial viability (4,9,45), prognosis (6), and selec-
tion of patients for coronary revascularization (3).
Applications that are immediately and readily avail-
able but not yet widely employed include absolute
measurement of MBF for detection of CAV (51), a
key prognostic factor, in patients with cardiac trans-
plants; quantitative measurement of the metabolic ratefor glucose usage and LV function for assessment of
response to metabolic therapy of stages C and D
CHF; objective treatment responses to device, gene,
or stem cell therapy (64), as defined by absolute MBF,
quantitative glucose metabolism, and LV function;
and quantitative 18F-FDG uptake to improve the
diagnosis of at least one treatable cause of cardiomy-
opathy, sarcoidosis (79). Finally, it is important to
emphasize that: 1) quantitative measurements of
MBF in the stenosis setting are linked to basic fluid
dynamic principles (80–82) which are the basis for
the invasive fractional flow reserve measurement;
and 2) quantitative measurements of the metabolic
rate for glucose usage depend on the value assigned
to the “lumped constant” which in fact is not
constant and requires correction depending on
physiological condition (83).
Future applications will depend on availability of
Figure 7. Typical LV Blood Pool and Myocardial TAC From PET
Dynamic Data Acquisition
Shown here are typical LV blood pool and myocardial time activity
(TAC) (upper panel) from a PET 18F-ﬂuorodeoxyglucose (FDG) dyna
acquisition. The lower panel shows the resulting Patlak plot for the
The slope of the line, Ki, is the uptake rate constant for the tracer a
multiplied by measured plasma glucose concentration divided by t
lumped constant (LC) gives the metabolic rate for glucose usage (m
(mol/min/100 g). Note that the plot can be implemented with an
spreadsheet, and the LC is not constant over all physiological cond
method for correcting it based on the myocardial FDG TAC has bee
posed (83). Other abbreviations as in Figures 1 and 4.18F-FDG
curves
mic data
data.
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300assessment of myocardial fatty acid metabolism and
autonomic nervous system function, both of which are
important clinically with respect to risk stratification
and evaluation of innovative, emerging therapies for
CHF. As illustrated earlier, optimal use of PET for
these applications will require state-of-the-art quanti-
tative methods to provide objective, measureable pa-myocardial cell membrane integrity
1
1
1
1
1
1
1
1
1
2008;118:968–76.mated, and followed over time, and are independent
of and inherently superior to even a skilled reader’s
subjective impression of a static PET image.
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